drugset / Trial / NCT03560518
Study of Rapastinel as Monotherapy in Patients With MDD
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
Timeline
- Start
- 2018-06-15
- Primary completion
- 2019-07-08
- Completion
- 2019-07-08
Outcome
Outcome not reported
Stopped (Business): “Business decision to stop the program.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rapastinel | Other / unclassified | 450 mg | Intravenous |
| Subject | Rapastinel | Other / unclassified | 900 mg | Intravenous |